NEWS FAQ INVESTORS WHY WE EXIST PIPELINE THE PAIN TRUTH ABOUT PAD OUR COMPANY FOLLOW THE PROGRESS Frequently asked questions. The more you know, the better you can treat PAD. What is JAN101? What is it indicated for? JAN101 is a twice-daily orally-dosed slow-release formulation of the FDA-approved compound, therapeutic sodium nitrite. Results from Phase 2a clinical trials support the use of sodium nitrite for the treatment and prevention of peripheral artery disease. An unexpected outcome of the studies was that some patients reported a significant reduction in PAD-associated pain. This led to our developing clinical protocols for PAD and PAD-associated pain for Phase 2b trials, expected to begin in second half of 2020. What is peripheral artery disease? Why is this drug important? How is it different? Where is JAN101 in the development pipeline? Who is JanOne and why are they licensing JAN101? Why start with peripheral artery disease (PAD)? Is JanOne in any way part of Bolling’s other work or political affiliations? What is JanOne? Is JanOne a new company? What’s next for JanOne? JanOne is a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. As a result, we hope to reduce the need for prescribing dangerous opioid drugs. Our first drug candidate is a treatment for Peripheral Arterial Disease (PAD), a condition that can cause severe pain and affects over 8.5 million people in the US alone. The company trades under the symbol JAN on the NASDAQ and continues to independently operate its subsidiary business – Appliance Recycling Centers of America, Inc (ARCA). Latest News JanOne on Twitter Why We Exist Pipeline The Pain Truth About PAD Our Company News FAQs Investors Contact

NEWS FAQ INVESTORS WHY WE EXIST PIPELINE THE PAIN TRUTH ABOUT PAD OUR COMPANY FOLLOW THE PROGRESS Need to know more about JanOne? Let us know. We are always looking for partners and talented people to help us advance our mission to see a world without pain and to reduce the need for opioids at the prescription pad. If you have questions or are interested in working with us, please let us know. We will respond within two business days. reason for contact Investor inquiry Partnership PAD or current treatment Careers Other Corporate Headquarters JanOne, Inc. 325 East Warm Springs Road Suite 102 Las Vegas, NV 89119 JanOne is a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. As a result, we hope to reduce the need for prescribing dangerous opioid drugs. Our first drug candidate is a treatment for Peripheral Arterial Disease (PAD), a condition that can cause severe pain and affects over 8.5 million people in the US alone. The company trades under the symbol JAN on the NASDAQ and continues to independently operate its subsidiary business – Appliance Recycling Centers of America, Inc (ARCA). Latest News JanOne on Twitter Why We Exist Pipeline The Pain Truth About PAD Our Company News FAQs Investors Contact